Ranivisio Europäische Union - Isländisch - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - augnlækningar - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Calcipotriol/Betamethasone Teva (Calcipotriol/Betamethasone ratiopharm) Smyrsli 50 míkrog/g + 0,5 mg/g Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

calcipotriol/betamethasone teva (calcipotriol/betamethasone ratiopharm) smyrsli 50 míkrog/g + 0,5 mg/g

teva b.v.* - betamethasonum díprópíónat; calcipotriolum inn - smyrsli - 50 míkrog/g + 0,5 mg/g

Tibinide Tafla 300 mg Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

tibinide tafla 300 mg

viatris aps - isoniazidum inn - tafla - 300 mg

Yesafili Europäische Union - Isländisch - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - augnlækningar - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Advate Europäische Union - Isländisch - EMA (European Medicines Agency)

advate

takeda manufacturing austria ag - octocog alfa - hemophilia a - antihemorrhagics - meðferð og fyrirbyggjandi blæðingar hjá sjúklingum með dreyrasýki a (meðfæddan þáttur viii-skortur). advate inniheldur ekki von willebrand þáttur í ly árangri magni og er því ekki fram í von willebrand sjúkdómur.

Eylea Europäische Union - Isländisch - EMA (European Medicines Agency)

eylea

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - augnlækningar - eylea er ætlað fyrir fullorðna fyrir meðferð:neovascular (blautur) aldri-tengjast ský á auga (rÍsa);sjón skert vegna ský bjúg efri að sjónhimnu æð stíflu (útibú rvo eða central rvo);sjón skert vegna sykursýki ský bjúg (dme);sjón skert vegna myopic æðu neovascularisation (myopic cnv).

ReFacto AF Europäische Union - Isländisch - EMA (European Medicines Agency)

refacto af

pfizer europe ma eeig - moroctocog alfa - hemophilia a - antihemorrhagics - meðferð og fyrirbyggjandi blæðingar hjá sjúklingum með dreyrasýki a (meðfæddan þáttur viii-skortur). refacto af er viðeigandi að nota í fullorðna og börn á öllum aldri, þar á meðal börn. refacto af inniheldur ekki von-willebrand þáttur, og þess vegna er ekki ætlað í von-willebrand er sjúkdómur.

Miacalcic Stungulyf/innrennslislyf, lausn 100 a.e./ml Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

miacalcic stungulyf/innrennslislyf, lausn 100 a.e./ml

essential pharma limited - calcitoninum inn - stungulyf/innrennslislyf, lausn - 100 a.e./ml

Natriumklorid Fresenius Kabi Innrennslislyf, lausn 9 g/1000 ml Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

natriumklorid fresenius kabi innrennslislyf, lausn 9 g/1000 ml

fresenius kabi ab - natrii chloridum - innrennslislyf, lausn - 9 g/1000 ml

Methergin Stungulyf, lausn 0,2 mg/ml Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

methergin stungulyf, lausn 0,2 mg/ml

essential pharma limited - methylergometrinum maleat - stungulyf, lausn - 0,2 mg/ml